Department of Microbiology and Infection Control, University Hospital of North Norway, N-9038 Tromsø, Norway.
Department of Medical Biology, UiT The Arctic University of Norway, N-9037 Tromsø, Norway.
Viruses. 2023 Feb 23;15(3):619. doi: 10.3390/v15030619.
To facilitate interpretation of clinical SARS-CoV-2 anti-spike IgG analyses post-vaccination, 82 healthcare workers were followed through three vaccination-regimens: two regimens were comprised of two doses of BNT162b2 three or six weeks apart, followed by a dose of mRNA-vaccine, and in the other regimen, the first dose was replaced by ChAdOx1 nCov-19. After each dose, anti-spike IgG was compared between regimens. As many participants became infected, anti-spike IgG persistence was compared between infected and uninfected participants. Thirteen to twenty-one days after the first dose, seroconversion, and the median anti-spike IgG level in the ChAdOx1 group was significantly lower than in the BNT162b2 groups (23 versus 68 and 73 AU/mL). The second dose caused a significant increase in anti-spike IgG, but the median level was lower in the BNT162b2-short-interval group (280 AU/mL), compared to the BNT162b2-long-interval (1075 AU/mL) and ChAdOx1 (1160 AU/mL) group. After the third dose, all groups showed increases to similar anti-spike IgG levels (2075-2390 AU/mL). Over the next half year, anti-spike IgG levels declined significantly in all groups, but appeared to persist longer after post-vaccination infection. This is the first three-dose study with one dose of ChAdOx1. Despite initial differences, all vaccine regimens gave similarly high antibody levels and persistence after the third dose.
为了便于解释接种疫苗后的 SARS-CoV-2 刺突 IgG 分析，对 82 名医护人员进行了三种疫苗接种方案的随访：两种方案均包含两剂 BNT162b2，间隔三或六周，然后接种一剂 mRNA 疫苗，而在另一种方案中，第一剂被 ChAdOx1 nCov-19 替代。在每次接种后，比较不同方案之间的刺突 IgG。由于许多参与者感染了，因此比较了感染和未感染参与者之间的刺突 IgG 持久性。在第一剂后 13-21 天，血清转化率，以及 ChAdOx1 组的中位刺突 IgG 水平明显低于 BNT162b2 组（23 与 68 和 73 AU/mL）。第二剂导致刺突 IgG 显著增加，但 BNT162b2 短间隔组（280 AU/mL）的中位水平低于 BNT162b2 长间隔组（1075 AU/mL）和 ChAdOx1 组（1160 AU/mL）。接种第三剂后，所有组均显示出相似的刺突 IgG 水平增加（2075-2390 AU/mL）。在接下来的半年中，所有组的刺突 IgG 水平均显著下降，但在接种疫苗后感染后似乎持续时间更长。这是第一项有一剂 ChAdOx1 的三剂量研究。尽管最初存在差异，但所有疫苗方案在第三剂后均产生了类似的高抗体水平和持久性。
